Denali Therapeutics (DNLI) Total Liabilities (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Total Liabilities data on file, last reported at $339.9 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $339.9 million, up 128.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $339.9 million (up 128.66% YoY), and the FY2025 annual result was $131.1 million, down 9.28% from the prior year.
• Total Liabilities grew to $339.9 million in Q1 2026 per DNLI's latest filing, from $131.1 million in the prior quarter.
• Over five years, Total Liabilities peaked at $442.6 million in Q1 2023 and troughed at $115.5 million in Q2 2024.
• A 5-year average of $226.9 million and a median of $139.2 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2024 and 2026: Total Liabilities slumped 71.62% in 2024, then surged 128.66% in 2026.
• A 5-year view of Total Liabilities shows it stood at $417.8 million in 2022, then plunged by 70.57% to $123.0 million in 2023, then rose by 17.51% to $144.5 million in 2024, then decreased by 9.28% to $131.1 million in 2025, then soared by 159.3% to $339.9 million in 2026.
• Business Quant data shows DNLI's Total Liabilities at $339.9 million in Q1 2026, $131.1 million in Q4 2025, and $129.4 million in Q3 2025.